Maddi Hebebrand, MC, Associate Editor

Renata Block, MMS, PA-C, and Amber Blair, MMS, PA-C, discuss the gratification of helping patients and the excitement of being on the cutting edge of research.

A recent review found the antifibrinolytic drug performed well in several clinical studies, none of which reported severe adverse events.

Stephen Tyring, MD, PhD, MBA, covers the burden of antimicrobial resistance and the need for alternative treatments.

Martin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.

The authorization of DermaSensor marks a milestone in AI-enabled devices, highlighting opportunities and challenges in their integration into clinical practice.

Laura Bush reflects on her term as SDPA president, discussing achievements, challenges, and the future of dermatology PAs in health care.

Rob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.

A recent review found that disparities and barriers, such as income, age, and location, can impede patient access to necessary care.

Ethan Sims, MD, spoke with Dermatology Times on having positive conversations, cutting down on waste, and how to get involved in change.

The program’s creator, Hubert Greenway, MD, has personally trained each of the fellowship’s 68 physicians in Mohs surgery.

A recent study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

VYNE Therapeutics Inc. shared that top-line data from the trial is expected in the second half of 2024.

A recent review found that teledermatology could improve patient access, increase efficiency, and cut down on costly hospital admissions.

The study found patients with vitiligo are at a lower risk of developing PD, but those with comorbid PD could face elevated mortality rates.

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

A recent study investigated the technology as a resource for patients seeking online medical information.

A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.

The trial reported complete hair regrowth for a number of participants, with 76% of a partial cohort meeting the primary endpoint of 30% improvement.

Researchers found patients with less than 95% hair loss at baseline reached median SALT score 2.4 or less, reflecting almost complete hair regrowth.

Karan Lal, DO, MS, FAAD, is a double-board certified pediatric and cosmetic dermatologist at Affiliated Dermatology in Scottsdale, Arizona.

Click here to answer today's poll and read more about providing patients with multidisciplinary care.

Researchers found evidence from numerous studies claiming LDI could improve rosacea symptoms and decrease flare-ups.

Upadacitinib is now available as a tablet or an oral solution for patients 2 years and older with pJIA as well as PsA.

The organization is highlighting stories and resources during Acne Awareness Month through the power of social media.

Dermatology Times is recapping our top expert interviews from the month of May.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

The study is the first to be approved by the European Medicines Agency to perform human clinical trials with a novel therapeutic mAb.

The study not only showed success for patients with severe psoriasis, but also suggested it may be worth trying before other biologics.

The largest patient study across the continent found a direct link between the extent of hair loss and the negative impact on quality of life.

A new acne-specific HRQoL questionnaire developed in Europe could help to create more comprehensive, individualized treatment plans.